Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications

Du, Pan; Li, Guangqing; Wu, Lu; Huang, Minger

doi:10.3389/fimmu.2022.1065379

Cited by 5 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the use of these indicators might enhance treatment outcomes and facilitate the development of novel targeted medicines. As an example of these previous statements, a study by Du [30] underlined that ERCC1 has been identified as a very promising biomarker for cervical cancer. Analysis of ERCC1 polymorphism suggests that it might serve as a valuable tool for predicting the likelihood of developing cervical cancer and the potentially hazardous side effects of therapy.…”

Section: Discussionmentioning

confidence: 96%

Why Is Surgery Still Done after Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer in Romania?

Voinea,

Bordea,

Chitoran

et al. 2024

Cancers

View full text Add to dashboard Cite

The incidence and mortality of cervical cancer are high in Romania compared to other European countries, particularly for locally advanced cervical cancer cases, which are predominant at the time of diagnosis. Widely accepted therapeutic guidelines indicate that the treatment for locally advanced cervical cancer consists of concurrent chemoradiotherapy (total dose 85–90 Gy at point A), with surgery not being necessary as it does not lead to improved survival and results in significant additional morbidity. In Romania, the treatment for locally advanced cervical cancer differs, involving lower-dose chemoradiotherapy (total dose 60–65 Gy at point A), followed by surgery, which, under these circumstances, ensures better local control. In this regard, we attempted to evaluate the role and necessity of surgery in Romania, considering that in our study, residual lesions were found in 55.84% of cases on resected specimens, especially in cases with unfavorable histology (adenocarcinoma and adenosquamous carcinoma). This type of surgery was associated with significant morbidity (28.22%) in our study. The recurrence rate was 24.21% for operated-on patients compared to 62% for non-operated-on patients receiving suboptimal concurrent chemotherapy alone. In conclusion, in Romania, surgery will continue to play a predominant role until radiotherapy achieves the desired effectiveness for local control.

show abstract

Section: Discussionmentioning

confidence: 96%

Why Is Surgery Still Done after Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer in Romania?

Voinea,

Bordea,

Chitoran

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…We used Haploview version 4.2 to choose the Haplotype tagging SNPs. They were chosen based on our previous research about lung cancer prognosis [9,34], and these genes were also associated with the outcome of multiple cancers [35,36]. And all the selected SNPs must satisfy the condition that the minor allele frequency (MAF) > 0.05 in the HapMap CHB population.…”

Section: Snp Selecting Dna Extraction and Genotypingmentioning

confidence: 99%

Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Zou,

Liu,

Qin

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Background: Lung cancer is still the most lethal malignancy in the world, according to the report of Cancer Statistics in 2021. Platinum-based chemotherapy combined with immunotherapy is the first-line treatment in lung cancer patients. However, the 5-year survival rate is always affected by the adverse reactions and drug resistance caused by platinum-based chemotherapy. DNA damage and repair system is one of the important mechanisms that can affect the response to chemotherapy and clinical outcomes in lung cancer patients. Objective: The objective of this study is to find the relationship between the polymorphisms of DNA repair genes with the prognosis of platinum-based chemotherapy in lung cancer patients. Patients and Methods: We performed genotyping in 17 single nucleotide polymorphisms (SNPs) of Excision Repair Cross-Complementation group (ERCC) genes and X-ray Repair Cross-Complementing (XRCC) genes of 345 lung cancer patients via Sequenom MassARRAY. We used Cox proportional hazard models, state, and plink to analyze the associations between SNPs and the prognosis of lung cancer patients. Results: We found that the ERCC5 rs873601 was associated with the overall survival time in lung cancer patients treated with platinum-based chemotherapy (p = 0.031). There were some polymorphisms that were related to the prognosis in specific subgroups of lung cancer. Rs873601 showed a great influence on the prognosis of patients more than 55 years, Small Cell Lung Cancer (SCLC), and smoking patients. Rs2444933 was associated with prognosis in age less than 55 years, SCLC, metastasis, and stage III/IV/ED patients. Rs3740051 played an important role in the prognosis of SCLC and metastasis patients. Rs1869641 was involved in the prognosis of SCLC patients. Rs1051685 was related to the prognosis in non-metastasis patients. Conclusion: The ERCC5 rs873601 (G>A) was a valuable biomarker for predicting the prognosis in lung cancer patients treated with platinum-based chemotherapy.

show abstract

“…They crosslink DNA molecules, causing extensive DNA damage and triggering apoptosis in cancer cells. However, in many cancer cells, the NER pathway is overactive due to the overexpression of ERCC1, which can diminish the therapeutic effectiveness of cisplatin and even lead to drug resistance [165][166][167][168]. Therefore, the design of selective NER/ERCC1 inhibitors holds promise in the enhancement of the efficacy of platinum-based treatments.…”

Section: Ercc1 Inhibitorsmentioning

confidence: 99%

Targeting the DNA Damage Response for Cancer Therapy

Wang,

Sun,

et al. 2023

IJMS

View full text Add to dashboard Cite

Over the course of long-term evolution, cells have developed intricate defense mechanisms in response to DNA damage; these mechanisms play a pivotal role in maintaining genomic stability. Defects in the DNA damage response pathways can give rise to various diseases, including cancer. The DNA damage response (DDR) system is instrumental in safeguarding genomic stability. The accumulation of DNA damage and the weakening of DDR function both promote the initiation and progression of tumors. Simultaneously, they offer opportunities and targets for cancer therapeutics. This article primarily elucidates the DNA damage repair pathways and the progress made in targeting key proteins within these pathways for cancer treatment. Among them, poly (ADP-ribose) polymerase 1 (PARP1) plays a crucial role in DDR, and inhibitors targeting PARP1 have garnered extensive attention in anticancer research. By delving into the realms of DNA damage and repair, we aspire to explore more precise and effective strategies for cancer therapy and to seek novel avenues for intervention.

show abstract

Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications

Cited by 5 publications

References 57 publications

Why Is Surgery Still Done after Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer in Romania?

Why Is Surgery Still Done after Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer in Romania?

Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Targeting the DNA Damage Response for Cancer Therapy

Contact Info

Product

Resources

About